DR REDDYS LABORATORIES LTD — Regulatory Filings 2019

Jul 19, 2019

•·· Dr.Reddy's �;•

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

July 19, 2019

Corporate Relationship Department BSE Limited Dalal Street, Fort Mumbai - 400 001 Fax Nos.: 022-22723121 / 22723719 / 22722037 / 22722039

National Stock Exchange of India Ltd. "Exchange Plaza" Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051 Fax Nos.: 022-26598120/ 26598237/ 26598238

Scrip Code: 500124

- Scrip Code: DRREDDY EO

Dear Sirs,

Sub: Press Release

Please find enclosed a Press Release on "Dr. Reddy's announces the launch of over-the­ counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended­ Release Tablets (fexofenadine HCl 60 mg and pseudoephedrine HCI 120 mg) in the U.S. Market"

This is for your information.

With regards,

\0 �[' ][. ] t) Sand�P ar y Secretary Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Press Release

•·· Dr.Reddy's �;•

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India.

==> picture [30 x 32] intentionally omitted <==

==> picture [90 x 17] intentionally omitted <==

==> picture [43 x 16] intentionally omitted <==

II/IEDIA RELATIONS

INVESTOR RELATIONS

AMIT AGARWAL MITAL\ SARKAR amlta@clrreddys.cm mita11.sar1ar@drreddys.com (PH: +91-40-49002135) (PH: +91-40- 49002121)

Dr. Reddy's announces the launch of over-the-counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets (fexofenadine HCI 60 mg and pseudoephedrine HCI 120 mg) in the U.S. Market

Hyderabad, India, July 19. 2019

For Immediate Release

Hyderabad, India and Princeton, NJ, USA. July 19, 2019 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP, an over-the­ counter (OTC) store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy's OTC Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP, are used:

• For temporary relief of symptoms due to hay fever or other upper respiratory allergies that include runny nose; sneezing; itchy, watery eyes; itching of the nose or throat

• For temporary relief of nasal congestion due to the common cold, hay fever or other upper respiratory allergies

• To reduce swelling of nasal passages

• For temporary relief of sinus congestion and pressure

• To temporarily restore freer breathing through the nose

"We are pleased to be expanding our pseudoephedrine-based product offering in time for the cough, cold and allergy season," says Milan Kalawadia, Senior Vice President and Head of US OTC and Specialty Rx Divisions, Dr. Reddy's Laboratories. "We look forward to collaborating with our customers to provide high-quality, affordable alternatives to consumers."

The Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets brand and generic had U.S. sales of approximately $44 million MAT for the most recent twelve months ending in May 2019 according to IRi *.

Dr. Reddy's OTC Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP are available in 20- and 30-count sizes.

Allegra-D[® ] 12 HR is a trademark of Aventisub II Inc. ,, �1,0, �:'. k eod May 19 ;;�:::::,:: : ;� 20 .. . . . . ........... ... ...... . ..... ....... . . .. . . . . ... tr iJ� V. ..... . . About Dr. Reddy's Dr Reddy's Laboratories Ltd (BSE 500124, NSE DRREDDY, NYSE RDY) Is an inlegraled pharmaceutical company, comm1lled to,p(_A\ltdlng�deija i,d innovative med1c1nes for heallh1er lives Through its lhree businesses - Pharmaceullcal Services & Acllve Ingredients, Global Genencs and Proprietary Products - Or Rtaay:�iofll[;] �rttolia of products and services including APls, custom pharmaceutical services, generics, biosimilars and differentiated formulations Our major therapeutic areas of focus are.gastrcilntes net, cardiovascular, diabetology, oncology, pain management and dermatology Dr Reddy's operates in markets across the globe, Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys&QID

Disclaimer: This press release may include statements of future expectations and other forward-looking statements lhal are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual resulls, performance or events to differ materially from those expressed or implied in such statements In addition to statements which are forward-looking by reason of context, lhe words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and !rends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues

The company assumes no obligation to update any informalion contained herein